Howard S. Hochster
Howard S. Hochster
Distinguished Professor of Medicine (oncology) Rutgers Cancer Institute of NJ, Rutgers University
Verified email at
Cited by
Cited by
VEGF inhibition and renal thrombotic microangiopathy
V Eremina, JA Jefferson, J Kowalewska, H Hochster, M Haas, J Weisstuch, ...
New England Journal of Medicine 358 (11), 1129-1136, 2008
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ...
New England Journal of Medicine 372 (20), 1909-1919, 2015
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
HS Hochster, LL Hart, RK Ramanathan, BH Childs, JD Hainsworth, ...
Journal of Clinical Oncology 26 (21), 3523-3529, 2008
NCCN guidelines insights: colon cancer, version 2.2018
AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ...
Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018
Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ...
Journal of the National Comprehensive Cancer Network 16 (7), 874-901, 2018
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
C Jacobs, G Lyman, E Velez-García, KS Sridhar, W Knight, H Hochster, ...
Journal of Clinical Oncology 10 (2), 257-263, 1992
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, L Cederquist, E Chan, YJ Chen, HS Cooper, ...
Journal of the National Comprehensive Cancer Network 15 (3), 370-398, 2017
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
M Tempero, W Plunkett, V Ruiz van Haperen, J Hainsworth, H Hochster, ...
Journal of Clinical Oncology 21 (18), 3402-3408, 2003
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ...
Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
LB Saltz, HJ Lenz, HL Kindler, HS Hochster, S Wadler, PM Hoff, ...
Journal of Clinical Oncology 25 (29), 4557-4561, 2007
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with …
E Poplin, Y Feng, J Berlin, ML Rothenberg, H Hochster, E Mitchell, ...
Journal of clinical oncology 27 (23), 3778-3785, 2009
Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB …
AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ...
Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
JL Speyer, MD Green, A Zeleniuch-Jacquotte, JC Wernz, M Rey, J Sanger, ...
Journal of Clinical Oncology 10 (1), 117-127, 1992
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein, W Verret, SP Hack, ...
The Lancet Oncology 21 (6), 808-820, 2020
Cancer stem cells: the promise and the potential
JA Ajani, S Song, HS Hochster, IB Steinberg
Seminars in oncology 42, S3-S17, 2015
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III …
H Hochster, E Weller, RD Gascoyne, TM Habermann, LI Gordon, T Ryan, ...
Journal of Clinical Oncology 27 (10), 1607, 2009
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ...
Nature reviews Clinical oncology 17 (12), 757-770, 2020
Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313
RK Ramanathan, SL McDonough, PA Philip, SR Hingorani, J Lacy, ...
Journal of Clinical Oncology 37 (13), 1062, 2019
Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma
RL Hayes, M Koslow, EM Hiesiger, KB Hymes, EJ Moore, DM Pierz, ...
Cancer 76 (5), 840-852, 1995
The system can't perform the operation now. Try again later.
Articles 1–20